

Solid Tumors

**A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors**

**Trial Status**  
Terminated

**Trial Runs In**  
11 Countries

**Trial Identifier**  
NCT02541604 2014-004697-41  
GO29664

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

---

**NCT02541604 2014-004697-41 GO29664**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
<= 30 Years

**Healthy Volunteers**  
No

---